Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: Analysis of the Center for Prostate Disease Research National Database

Emmanuel Antonarakis, Yongmei Chen, Sally I. Elsamanoudi, Stephen A. Brassell, Mario V. Da Rocha, Mario Eisenberger, David G. McLeod

Research output: Contribution to journalArticle

Abstract

OBJECTIVE To describe metastasis-free survival (MFS) and overall survival (OS) among men with prostate-specific antigen (PSA)-recurrent prostate cancer after radical prostatectomy who did not receive additional therapy until metastasis, using a multicentre database capturing a wide ethnic mix. PATIENTS AND METHODS A retrospective analysis of the Center for Prostate Disease Research National Database (comprised of five US military hospitals and one civilian centre) was performed for patients with PSA relapse (≥0.2 ng/mL) after radical prostatectomy who had no additional therapy until the time of radiographic metastatic disease. We investigated factors influencing metastasis and all-cause mortality using univariate and multivariate Cox regression analysis. RESULTS There were a total of 346 men who underwent radical prostatectomy between May 1983 and November 2008 and fulfilled the entry criteria. All patients had information on survival and 190 men had information on metastasis. Among patients with survival data (n= 346), 10-year OS was 79% after a median follow-up of 8.6 years from biochemical recurrence. Among men with metastasis data (n= 190), 10-year MFS was 46% after a median follow-up of 7.5 years. In Cox regressions, four clinical factors (Gleason score, pathological stage, time to PSA relapse and PSA doubling time), as well as age, were predictive of OS and/or MFS in univariate analysis, although only PSA doubling time (≥9 vs 3-8.9 vs

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalBJU International
Volume108
Issue number3
DOIs
StatePublished - Aug 2011

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Prostate
Prostatic Neoplasms
Databases
Neoplasm Metastasis
Survival
Research
Recurrence
Military Hospitals
Neoplasm Grading
Regression Analysis
Mortality
Therapeutics

Keywords

  • metastasis-free survival
  • natural history
  • overall survival
  • prostate cancer
  • PSA recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy : Analysis of the Center for Prostate Disease Research National Database. / Antonarakis, Emmanuel; Chen, Yongmei; Elsamanoudi, Sally I.; Brassell, Stephen A.; Da Rocha, Mario V.; Eisenberger, Mario; McLeod, David G.

In: BJU International, Vol. 108, No. 3, 08.2011, p. 378-385.

Research output: Contribution to journalArticle

@article{d05728709988430f83f5e463998a6577,
title = "Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: Analysis of the Center for Prostate Disease Research National Database",
abstract = "OBJECTIVE To describe metastasis-free survival (MFS) and overall survival (OS) among men with prostate-specific antigen (PSA)-recurrent prostate cancer after radical prostatectomy who did not receive additional therapy until metastasis, using a multicentre database capturing a wide ethnic mix. PATIENTS AND METHODS A retrospective analysis of the Center for Prostate Disease Research National Database (comprised of five US military hospitals and one civilian centre) was performed for patients with PSA relapse (≥0.2 ng/mL) after radical prostatectomy who had no additional therapy until the time of radiographic metastatic disease. We investigated factors influencing metastasis and all-cause mortality using univariate and multivariate Cox regression analysis. RESULTS There were a total of 346 men who underwent radical prostatectomy between May 1983 and November 2008 and fulfilled the entry criteria. All patients had information on survival and 190 men had information on metastasis. Among patients with survival data (n= 346), 10-year OS was 79{\%} after a median follow-up of 8.6 years from biochemical recurrence. Among men with metastasis data (n= 190), 10-year MFS was 46{\%} after a median follow-up of 7.5 years. In Cox regressions, four clinical factors (Gleason score, pathological stage, time to PSA relapse and PSA doubling time), as well as age, were predictive of OS and/or MFS in univariate analysis, although only PSA doubling time (≥9 vs 3-8.9 vs",
keywords = "metastasis-free survival, natural history, overall survival, prostate cancer, PSA recurrence",
author = "Emmanuel Antonarakis and Yongmei Chen and Elsamanoudi, {Sally I.} and Brassell, {Stephen A.} and {Da Rocha}, {Mario V.} and Mario Eisenberger and McLeod, {David G.}",
year = "2011",
month = "8",
doi = "10.1111/j.1464-410X.2010.09878.x",
language = "English (US)",
volume = "108",
pages = "378--385",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy

T2 - Analysis of the Center for Prostate Disease Research National Database

AU - Antonarakis, Emmanuel

AU - Chen, Yongmei

AU - Elsamanoudi, Sally I.

AU - Brassell, Stephen A.

AU - Da Rocha, Mario V.

AU - Eisenberger, Mario

AU - McLeod, David G.

PY - 2011/8

Y1 - 2011/8

N2 - OBJECTIVE To describe metastasis-free survival (MFS) and overall survival (OS) among men with prostate-specific antigen (PSA)-recurrent prostate cancer after radical prostatectomy who did not receive additional therapy until metastasis, using a multicentre database capturing a wide ethnic mix. PATIENTS AND METHODS A retrospective analysis of the Center for Prostate Disease Research National Database (comprised of five US military hospitals and one civilian centre) was performed for patients with PSA relapse (≥0.2 ng/mL) after radical prostatectomy who had no additional therapy until the time of radiographic metastatic disease. We investigated factors influencing metastasis and all-cause mortality using univariate and multivariate Cox regression analysis. RESULTS There were a total of 346 men who underwent radical prostatectomy between May 1983 and November 2008 and fulfilled the entry criteria. All patients had information on survival and 190 men had information on metastasis. Among patients with survival data (n= 346), 10-year OS was 79% after a median follow-up of 8.6 years from biochemical recurrence. Among men with metastasis data (n= 190), 10-year MFS was 46% after a median follow-up of 7.5 years. In Cox regressions, four clinical factors (Gleason score, pathological stage, time to PSA relapse and PSA doubling time), as well as age, were predictive of OS and/or MFS in univariate analysis, although only PSA doubling time (≥9 vs 3-8.9 vs

AB - OBJECTIVE To describe metastasis-free survival (MFS) and overall survival (OS) among men with prostate-specific antigen (PSA)-recurrent prostate cancer after radical prostatectomy who did not receive additional therapy until metastasis, using a multicentre database capturing a wide ethnic mix. PATIENTS AND METHODS A retrospective analysis of the Center for Prostate Disease Research National Database (comprised of five US military hospitals and one civilian centre) was performed for patients with PSA relapse (≥0.2 ng/mL) after radical prostatectomy who had no additional therapy until the time of radiographic metastatic disease. We investigated factors influencing metastasis and all-cause mortality using univariate and multivariate Cox regression analysis. RESULTS There were a total of 346 men who underwent radical prostatectomy between May 1983 and November 2008 and fulfilled the entry criteria. All patients had information on survival and 190 men had information on metastasis. Among patients with survival data (n= 346), 10-year OS was 79% after a median follow-up of 8.6 years from biochemical recurrence. Among men with metastasis data (n= 190), 10-year MFS was 46% after a median follow-up of 7.5 years. In Cox regressions, four clinical factors (Gleason score, pathological stage, time to PSA relapse and PSA doubling time), as well as age, were predictive of OS and/or MFS in univariate analysis, although only PSA doubling time (≥9 vs 3-8.9 vs

KW - metastasis-free survival

KW - natural history

KW - overall survival

KW - prostate cancer

KW - PSA recurrence

UR - http://www.scopus.com/inward/record.url?scp=79960596998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960596998&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2010.09878.x

DO - 10.1111/j.1464-410X.2010.09878.x

M3 - Article

C2 - 21091976

AN - SCOPUS:79960596998

VL - 108

SP - 378

EP - 385

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -